[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | E-mail ]

Turkish Journal of Cancer
2005, Volume 35, Number 2, Page(s) 061-069
[ Summary ] [ Full Text ] [ PDF ]
Treatment approaches for metastatic breast cancer in Turkey
Breast cancer practice pattern study group

Until today, a widely accepted treatment approach has not yet been defined for metastatic breast cancer. A noncomparative, non-interventional observational study was conducted to evaluate first-line systemic treatment approaches in metastatic breast cancer patients in Turkey. A total of 372 metastatic breast cancer patients from 34 institutes were taken into the study. Median age at diagnosis was 50 (21-84). Sixty-five percent of the patients were postmenopausal. Thirty percent were metastatic at first admission, the median time to metastasis for the rest was 28.5 months (3-205). Hormone receptor status was evaluated in 71% of patients and 57% were found receptor (+). Hormonal therapy was not considered in first-line for 32% of receptor (+) patients. For patients who were metastatic at first admission, anthracycline-based regimens were the most common choice of treatment as first-line. Overall in the first-line, taxanes were preferred for 13% and 8% of premenopausal and postmenopausal patients, respectively. Receptor status was found to significantly affect the choice of treatment for all subgroups, while age of onset and site of metastasis were significant for only postmenopausal patients.[Turk J Cancer 2005;35(2):61-69].

[ Summary ] [ Full Text ] [ PDF ]
[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | E-mail ]